Company profile
Chemomab Therapeutics Ltd.
NASDAQ:CMMBBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Nebokitug | phase1 | — | 1 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05824156 | phase2 | completed | 2021-02-24 | 2022-08-15 | ChemomAb Ltd. | CM-101 in NASH Patients - The SPLASH Study |
| NCT04595825 | phase2 | completed | 2020-10-01 | 2025-01-10 | ChemomAb Ltd. | CM-101 in PSC Patients -The SPRING Study |
| NCT06025851 | phase1 | completed | 2017-07-24 | 2018-02-18 | ChemomAb Ltd. | Intravenous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects |
| NCT06210945 | phase2 | suspended | 2026-09-01 | 2028-06-01 | ChemomAb Ltd. | Study to Evaluate the Safety, Tolerability, and Activity of CM-101 in Patients With Systemic Sclerosis |
| NCT06037577 | phase1 | completed | 2019-03-05 | 2019-05-05 | ChemomAb Ltd. | Subcutaneous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects |
FDA applications (0)
No records yet.